RPR120844, a Novel, Specific Inhibitor of Coagulation Factor Xa Inhibits Venous Thrombosis in the Rabbit

Jeffrey S. Bostwick; Ross Bentley; Suzanne Morgan; Karen Brown; Valeria Chu; Richard W. Ewing; Alfred P. Spada; Henry Pauls; Mark H. Perrone; Christopher T. Dunwiddie; Robert J. Leadley Jr.

doi:10.1055/s-0037-1614434

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 81(01): 157-160
DOI: 10.1055/s-0037-1614434

Review Article

Schattauer GmbH

RPR120844, a Novel, Specific Inhibitor of Coagulation Factor Xa Inhibits Venous Thrombosis in the Rabbit

Jeffrey S. Bostwick

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Ross Bentley

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Suzanne Morgan

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Karen Brown

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Valeria Chu

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Richard W. Ewing

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Alfred P. Spada

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Henry Pauls

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Mark H. Perrone

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Christopher T. Dunwiddie^*

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

,

Robert J. Leadley Jr.

¹From the Cardiovascular Drug Discovery, Rhône-Poulenc Rorer Research and Development, Collegeville, PA, USA

› Author Affiliations

References
1 Weitz I J, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound throm-bin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by anti-thrombin III-independent inhibitors. J Clin Invest 1990; 86 (August) 385-91.
2 Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of throm-bin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92: 962-7.
3 Eisenberg PR, Siegel JE, Abdenschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91 (May) 1877-83.
4 McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombuS-associated factor Xa. Arterioscler Thromb Vasc Biol 1996; 16: 1285-91.
5 Schaffer LW, Davidson JT, Vlasuk GP, Dunwiddie CT, Sigel PKS. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arteriosclerosis and Thrombosis 1992; 12: 879-85.
6 Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF. Selective inhbition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrin 1996; 7: 39-48.
7 Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and Tick Anticoagulant Peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-62.
8 Rebello SS, Blank HS, Rote WE, Vlasuk GP, Lucchesi BR. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharm Exp Ther 1997; 283: 91-9.
9 Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9.
10 Herbert JM, Bernat A, Dol R, Herault JP, Crepon B, Lormeau JC. DX 9065, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharm Exp Ther 1996; 276: 1030-8.
11 Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovascular Drug Reviews 1997; 15 (01) 1-26.
12 Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, Koshio H. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Brit J Pharmacol 1998; 123: 92-6.
13 National Research Council. Guide for the care and use of laboratory animals. Washington, D.C: National Academy Press; 1996
14 Kotze HF, Lamprecht S, Badenhorst PN, Roodt JP, vanWyk V. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects. Thromb Haemost 1997; 77: 1137-42.
15 Lyle EM, Fujita T, Conner MW, Connolly TM, Vlasuk GP, Lynch Jr. JL. Effect of inhibitors of factor Xa or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplasty injury. J Pharmacol Toxicol Meth 1995; 33: 53-61.